Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av GSK5458514 administrerad ensam eller i kombination med andra anti-cancermedel hos deltagare med prostratcancer

1 oktober 2026 uppdaterad av: GlaxoSmithKline

En fas 1/2 första-i-mänsklig, öppen etikett-, multicenter-, dosupptrappning och expansionsstudie av GSK5458514 PSMA-inriktning på Cell Engage ensam eller i kombination med andra anti-cancermedel i vuxna deltagare med metastaserande kastreringsresistent prostatacancer (MCRPC)

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

85

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Lyon, Frankrike, 69373
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Armelle Vinceneux
      • Villejuif, Frankrike, 94805
        • Rekrytering
        • GSK Investigational Site
        • Huvudutredare:
          • Yohann Loriot
        • Kontakt:
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85054
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Huvudutredare:
          • Yousef Zakharia
        • Kontakt:
    • Colorado
      • Denver, Colorado, Förenta staterna, 80218-1234
        • Rekrytering
        • GSK Investigational Site
        • Huvudutredare:
          • Gerald Falchook
        • Kontakt:
        • Kontakt:
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06510
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Daniel Petrylak
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55905
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Dan Childs
    • New Jersey
      • East Brunswick, New Jersey, Förenta staterna, 08816
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Bruno Fang
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Benjamin Garmezy
      • Kanagawa, Japan, 232-0024
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Takashi Kawahara
      • Tokyo, Japan, 104-0045
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Tatsunori Shimoi
      • Tokyo, Japan, 135-8550
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Yuji Miura
    • Ontario
      • Toronto, Ontario, Kanada, M4N 3M5
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Daniel Khalaf
    • Quebec
      • Montreal, Quebec, Kanada, H4A 3J1
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Ramy Saleh
      • Montreal, Quebec, Kanada, H3T 1E2
        • Rekrytering
        • GSK Investigational Site
        • Huvudutredare:
          • April Rose
        • Kontakt:
        • Kontakt:
      • Badajoz, Spanien, 06080
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Marta González Cordero
      • Barcelona, Spanien, 08023
        • Rekrytering
        • GSK Investigational Site
        • Huvudutredare:
          • Tatiana Hernandez
        • Kontakt:
        • Kontakt:
      • Madrid, Spanien, 28040
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Bernard Doger
      • Madrid, Spanien, 28050
        • Rekrytering
        • GSK Investigational Site
        • Huvudutredare:
          • Emiliano Calvo Aller
        • Kontakt:
        • Kontakt:
      • Málaga, Spanien, 29010
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Lucia Oliva Fernandez
      • Pozuelo de AlarcOn Madr, Spanien, 28223
        • Rekrytering
        • GSK Investigational Site
        • Huvudutredare:
          • VALENTINA BONI
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol.
  • Male participants greater than equal to (>=)18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.

Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after the last dose of study intervention:

Refrain from donating sperm

PLUS either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

Must agree to use contraception as detailed below:

Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.

  • Participants with mCRPC:

    • Histologically or cytologically confirmed adenocarcinoma of the prostate
    • Metastatic disease diagnosed either by radiologic imaging (Positron emission tomography [PET]- Computed tomography [CT]) and/or regular CT and/or Magnetic resonance imaging (MRI) and/or bone scan
    • Castration-resistant status as per PCWG3 criteria
  • Has prior novel anti-androgen receptor therapy failure and had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer.

  • Has (1) at least 1 soft tissue target lesion per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) OR (2) if Non-Target soft tissue disease only per PCWG3-modified RECIST 1.1, may be included if a rise in Prostate-specific antigen (PSA) on 2 successive determinations at least 1 week apart (the most recent screening measurement must have been >= 2 nanograms per milliliter (ng/mL) with testosterone levels <50 nanograms per deciliter (ng/dL), OR (3) bone disease defined by PCWG3 (2 or more lesions on bone scan at screening), as determined by the investigator.

  • Documented disease progression on most recent systemic anti-cancer therapy defined by fulfilling at least 1 of the PCWG3 criteria

  • Have serum testosterone <50 ng/dL (<1.7 nM). Patients must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a Gonadotropin-releasing hormone (GnRH) agonist or antagonist; this therapy must have been initiated at least 4 weeks prior to randomization and treatment must be continued throughout the study.

  • Eastern Cooperative Oncology Group (ECOG) performance status <=1, with no deterioration in the 2 weeks before step-up treatment period Day 1.

  • Have supplied tumor tissue from a newly obtained biopsy or archival tumor tissue for retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue preferably taken after the completion of the participant's last line of therapy prior to the first dose of study drug is acceptable.

  • Participants must have adequate organ function

Exclusion criteria:

  • Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any histology different from adenocarcinoma.

  • History of central nervous system (CNS) metastases or leptomeningeal disease.

  • Diagnosis of invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:

    • History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study
    • Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, and/or in situ breast cancer may be enrolled
  • Has ongoing adverse reaction(s) from prior therapy that have not recovered to <=Grade 1 or to the baseline status preceding prior therapy, excluding [e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Confirmed history or recurrent autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).

  • Has evidence of interstitial lung disease, non-infectious pneumonitis, and/or a history of interstitial lung disease, non-infectious pneumonitis that required steroid.

  • Has received any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 30 days prior to first dose of study intervention.

  • Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received <2 cycles.

  • Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy and PSMA (T cell engager) TCE/ Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE).

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.

  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • History of severe neurological or psychiatric disorder, including epilepsy, dementia, or major depression deemed to interfere with study assessments.

  • Has had any major surgery (such as craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks prior to first dose of study intervention.

  • Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for >=2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.

Liver safety exclusion criteria:

  • Has an Alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or >5x ULN if documented history of liver metastases.
  • Has a total bilirubin value >1.5x ULN.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Has documented presence of Hepatitis B surface antigen (HBsAg), at screening or within 3 months prior to the first dose of study intervention.
  • Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to Cycle 1 Day 1 unless the participant can meet the following criteria: NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria
  • Has a positive HCV ribonucleic acid (RNA) test result at screening or within 3 months prior to the first dose of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
  • Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the investigator.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Del 1: Dosökning av GSK5458514 Monoterapi

GSK5458514 will be administered.

Experimentell: Del 2: Dosutvidgning av GSK5458514 Monoterapi

GSK5458514 will be administered.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Antal deltagare med dosbegränsande toxicitet (DLTS) under DLT -observationsperioden
Tidsram: Upp till 28 dagar
Upp till 28 dagar
Antal deltagare med biverkningar (AES), allvarliga biverkningar (SAE), genom svårighetsgrad
Tidsram: Upp till cirka 29 månader
Upp till cirka 29 månader
Antal deltagare med AES som leder till dosändringar
Tidsram: Upp till cirka 29 månader
Upp till cirka 29 månader

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Område under koncentration från 0 till T (AUC 0-T) av GSK5458514
Tidsram: Upp till cirka 32 månader
Upp till cirka 32 månader
Maximal koncentration (CMAX) av GSK5458514
Tidsram: Upp till cirka 32 månader
Upp till cirka 32 månader
Tid att nå maximal koncentration (TMAX) av GSK5458514
Tidsram: Upp till cirka 32 månader
Upp till cirka 32 månader
Antal deltagare med anti-läkemedelsantikroppar (ADA) mot GSK5458514
Tidsram: Upp till cirka 32 månader
Upp till cirka 32 månader
ADA: s titrar mot GSK5458514
Tidsram: Upp till cirka 32 månader
Upp till cirka 32 månader
Prostate-specific Antigen Decrease From Baseline >=50% (PSA50) Response Rate
Tidsram: Up to approximately 32 months

PSA50 response rate is defined as percentage of participants with a decrease of >=50% in the PSA concentration from the baseline PSA value, confirmed at least 3 weeks later.

Up to approximately 32 months
Objective Response Rate (ORR)
Tidsram: Up to approximately 32 months

ORR is defined as the percentage of participants in the ORR Evaluable set who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) per prostate cancer working group 3 (PCWG3) guidelines as assessed by investigator.

Up to approximately 32 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: GSK Clinical Trials, GlaxoSmithKline

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 juni 2025

Primärt slutförande (Beräknad)

26 oktober 2027

Avslutad studie (Beräknad)

9 augusti 2028

Studieregistreringsdatum

Först inskickad

22 maj 2025

Först inskickad som uppfyllde QC-kriterierna

22 maj 2025

Första postat (Faktisk)

25 maj 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Tidsram för IPD-delning

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Kriterier för IPD Sharing Access

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera